Trial NCT04436276
Publication Sadoff J, N Engl J Med, 2021
Primary outcome on the report: The primary end points were the safety and re-actogenicity of each dose schedule. Follow-up visits to evaluate reactogenicity, safety, and im-munogenicity were scheduled on days 7, 28, and 71 after vaccination in each cohort.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.